Abstract
In recent years, the innovation of gene-editing tools such as the CRISPR/Cas9 system improves the translational gap of treatments mediated by gene therapy. The privileges of CRISPR/Cas9 such as working in living cells and organs candidate this technology for using in research and treatment of the central nervous system (CNS) disorders. Parkinson’s disease (PD) is a common, debilitating, neurodegenerative disorder which occurs due to loss of dopaminergic neurons and is associated with progressive motor dysfunction. Knowledge about the pathophysiological basis of PD has altered the classification system of PD, which manifests in familial and sporadic forms. The first genetic linkage studies in PD demonstrated the involvement of Synuclein alpha (SNCA) mutations and SNCA genomic duplications in the pathogenesis of PD familial forms. Subsequent studies have also insinuated mutations in leucine repeat kinase-2 (LRRK2), Parkin, PTEN-induced putative kinase 1 (PINK1), as well as DJ-1 causing familial forms of PD. This review will attempt to discuss the structure, function, and development in genome editing mediated by CRISP/Cas9 system. Further, it describes the genes involved in the pathogenesis of PD and the pertinent alterations to them. We will pursue this line by delineating the PD linkage studies in which CRISPR system was employed. Finally, we will discuss the pros and cons of CRISPR employment vis-à-vis the process of genome editing in PD patients’ iPSCs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abeliovich A et al (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:239–252
Abizaid A et al (2006) Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Investig 116:3229–3239. https://doi.org/10.1172/jci29867
Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW (2003) The role of pathogenic DJ-1 mutations in Parkinson’s disease. Ann Neurol 54(3):283–286. https://doi.org/10.1002/ana.10675
Ai SX et al (2014) Hypomethylation of SNCA in blood of patients with sporadic Parkinson’s disease. J Neurol Sci 337:123–128. https://doi.org/10.1016/j.jns.2013.11.033
Anand VS, Braithwaite SP (2009) LRRK2 in Parkinson’s disease: biochemical functions. FEBS J 276(22):6428–6435. https://doi.org/10.1111/j.1742-4658.2009.07341.x
Andrews ZB et al (2009) Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. J Neurosci 29(45):14057–14065. https://doi.org/10.1523/jneurosci.3890-09.2009
Annesi G et al (2005) DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral sclerosis complex. Ann Neurol 58(5):803–807. https://doi.org/10.1002/ana.20666
Arkinson C, Walden H (2018) Parkin function in Parkinson’s disease. Science 360:267–268. https://doi.org/10.1126/science.aar6606
Arruda VR, Doshi BS, Samelson-Jones BJ (2017) Novel approaches to hemophilia therapy: successes and challenges. Blood 130:2251–2256. https://doi.org/10.1182/blood-2017-08-742312
Athauda D, Foltynie T (2016) Challenges in detecting disease modification in Parkinson’s disease clinical trials. Parkinsonism Relat Disord 32:1–11. https://doi.org/10.1016/j.parkreldis.2016.07.019
Basu S, Adams L, Guhathakurta S, Kim YS (2017) A novel tool for monitoring endogenous alpha-synuclein transcription by NanoLuciferase tag insertion at the 3′end using CRISPR-Cas9 genome editing technique. Sci Rep 7:45883. https://doi.org/10.1038/srep45883
Blesa J, Przedborski S (2014) Parkinson’s disease: animal models and dopaminergic cell vulnerability. Front Neuroanat 8:155. https://doi.org/10.3389/fnana.2014.00155
Bonifati V et al (2002) Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Ann Neurol 51(2):253–256
Bonifati V et al (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299(5604):256–259. https://doi.org/10.1126/science.1077209
Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318:121–134. https://doi.org/10.1007/s00441-004-0956-9
Byers B, Lee HL, Reijo Pera R (2012) Modeling Parkinson’s disease using induced pluripotent stem cells. Curr Neurol Neurosci Rep 12:237–242. https://doi.org/10.1007/s11910-012-0270-y
Chang D et al (2017) A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci. Nat Genet 49(10):1511–1516. https://doi.org/10.1038/ng.3955
Chen Y et al (2018) Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene. Eur J Neurosci. https://doi.org/10.1111/ejn.14286
Cheng H et al (2002) Isolation and characterization of a human novel RAB (RAB39B) gene. Cytogenet Genome Res 97(1–2):72–75. https://doi.org/10.1159/000064047
Cheng MY, Bittman EL, Hattar S, Zhou QY (2005) Regulation of prokineticin 2 expression by light and the circadian clock. BMC Neurosci 6(1):17. https://doi.org/10.1186/1471-2202-6-17
Chesselet MF, Richter F (2011) Modelling of Parkinson’s disease in mice. Lancet Neurol 10:1108–1118. https://doi.org/10.1016/s1474-4422(11)70227-7
Chu Y, Kordower JH (2010) Lewy body pathology in fetal grafts. Ann N Y Acad Sci 1184:55–67. https://doi.org/10.1111/j.1749-6632.2009.05229.x
Dawson TM, Golde TE, Lagier-Tourenne C (2018) Animal models of neurodegenerative diseases. Nat Neurosci 21:1370–1379. https://doi.org/10.1038/s41593-018-0236-8
de Boni L, Tierling S, Roeber S, Walter J, Giese A, Kretzschmar HA (2011) Next-generation sequencing reveals regional differences of the alpha-synuclein methylation state independent of Lewy body disease. NeuroMol Med 13:310–320. https://doi.org/10.1007/s12017-011-8163-9
DeJesus R et al (2016) Functional CRISPR screening identifies the ufmylation pathway as a regulator of SQSTM1/p62. ELife 5:e17290. https://doi.org/10.7554/elife.17290
Dekel-Naftali M et al (2012) Screening of human pluripotent stem cells using CGH and FISH reveals low-grade mosaic aneuploidy and a recurrent amplification of chromosome 1q. Eur J Hum Genet 20(12):1248–1255. https://doi.org/10.1038/ejhg.2012.128
Devine MJ, Gwinn K, Singleton A, Hardy J (2011) Parkinson’s disease and alpha-synuclein expression. Mov Disord 26:2160–2168. https://doi.org/10.1002/mds.23948
Dolezalova D et al (2014) Pig models of neurodegenerative disorders: utilization in cell replacement-based preclinical safety and efficacy studies. J Comp Neurol 522:2784–2801. https://doi.org/10.1002/cne.23575
Emamalizadeh B et al (2014) RIT2, a susceptibility gene for Parkinson’s disease in Iranian population. Neurobiol Aging 35(12):e27–e28. https://doi.org/10.1016/j.neurobiolaging.2014.07.013
Farrer M et al (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 55:174–179. https://doi.org/10.1002/ana.10846
Ferreira M, Massano J (2017) An updated review of Parkinson’s disease genetics and clinicopathological correlations. Acta Neurol Scand 135:273–284. https://doi.org/10.1111/ane.12616
Flierl A et al (2014) Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication. PLoS ONE 9:e112413. https://doi.org/10.1371/journal.pone.0112413
Floyd BJ et al (2016) Mitochondrial protein interaction mapping identifies regulators of respiratory chain function. Mol Cell 63:621–632. https://doi.org/10.1016/j.molcel.2016.06.033
Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD (2013) High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31:822–826. https://doi.org/10.1038/nbt.2623
Fujiwara H et al (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4(2):160–164. https://doi.org/10.1038/ncb748
Gaj T, Gersbach CA, Barbas CF III (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31(7):397–405. https://doi.org/10.1016/j.tibtech.2013.04.004
Gao Y, Wilson GR, Bozaoglu K, Elefanty AG, Stanley EG, Dottori M, Lockhart PJ (2018) Generation of RAB39B knockout isogenic human embryonic stem cell lines to model RAB39B-mediated Parkinson’s disease. Stem Cell Res 28:161–164. https://doi.org/10.1016/j.scr.2018.02.015
Ghosh A et al (2016) Mitoapocynin treatment protects against neuroinflammation and dopaminergic neurodegeneration in a preclinical animal model of parkinson’s disease. J Neuroimmune Pharmacol 11:259–278. https://doi.org/10.1007/s11481-016-9650-4
Gorbatyuk OS et al (2010) In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther 18:1450–1457. https://doi.org/10.1038/mt.2010.115
Gordon R, Anantharam V, Kanthasamy AG, Kanthasamy A (2012) Proteolytic activation of proapoptotic kinase protein kinase Cdelta by tumor necrosis factor alpha death receptor signaling in dopaminergic neurons during neuroinflammation. J Neuroinflammation 9:82. https://doi.org/10.1186/1742-2094-9-82
Gordon R et al (2016a) Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration. Nat Commun 7:12932. https://doi.org/10.1038/ncomms12932
Gordon R et al (2016b) Protein kinase Cdelta upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson’s disease. Neurobiol Dis 93:96–114. https://doi.org/10.1016/j.nbd.2016.04.008
Gore A et al (2011) Somatic coding mutations in human induced pluripotent stem cells. Nature 471:63–67. https://doi.org/10.1038/nature09805
Grundemann J, Schlaudraff F, Haeckel O, Liss B (2008) Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson’s disease. Nucleic Acids Res 36:e38. https://doi.org/10.1093/nar/gkn084
Guhathakurta S, Bok E, Evangelista BA, Kim YS (2017) Deregulation of alpha-synuclein in Parkinson’s disease: insight from epigenetic structure and transcriptional regulation of SNCA. Prog Neurobiol 154:21–36. https://doi.org/10.1016/j.pneurobio.2017.04.004
Hanrott K, Murray TK, Orfali Z, Ward M, Finlay C, O’Neill MJ, Wonnacott S (2008) Differential activation of PKC delta in the substantia nigra of rats following striatal or nigral 6-hydroxydopamine lesions. Eur J Neurosci 27(5):1086–1096. https://doi.org/10.1111/j.1460-9568.2008.06097.x
Hasegawa K, Stoessl AJ, Yokoyama T, Kowa H, Wszolek ZK, Yagishita S (2009) Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 15(4):300–306. https://doi.org/10.1016/j.parkreldis.2008.07.010
Healy DG et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol 7(7):583–590. https://doi.org/10.1016/s1474-4422(08)70117-0
Higashi S et al (2015) p13 overexpression in pancreatic beta-cells ameliorates type 2 diabetes in high-fat-fed mice. Biochem Biophys Res Commun 461(4):612–617. https://doi.org/10.1016/j.bbrc.2015.04.074
Hussein SM et al (2011) Copy number variation and selection during reprogramming to pluripotency. Nature 471:58–62. https://doi.org/10.1038/nature09871
Inoue N et al (2018) Knockdown of the mitochondria-localized protein p13 protects against experimental parkinsonism. EMBO Rep. https://doi.org/10.15252/embr.201744860
Jamshidi J et al (2014) HLA-DRA is associated with Parkinson’s disease in Iranian population. Int J Immunogenet 41:508–511. https://doi.org/10.1111/iji.12151
Jian F et al (2018) Sam50 Regulates PINK1-Parkin-mediated mitophagy by controlling PINK1 stability and mitochondrial morphology. Cell Rep 23(10):2989–3005. https://doi.org/10.1016/j.celrep.2018.05.015
Jowaed A, Schmitt I, Kaut O, Wullner U (2010) Methylation regulates alpha-synuclein expression and is decreased in Parkinson’s disease patients’ brains. J Neurosci 30:6355–6359. https://doi.org/10.1523/jneurosci.6119-09.2010
Kantor B et al (2018) Downregulation of SNCA expression by targeted editing of DNA methylation: a potential strategy for precision therapy in PD. Mol Ther 26:2638–2649. https://doi.org/10.1016/j.ymthe.2018.08.019
Khodr CE et al (2011) An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson’s disease, but displays toxicity in dopamine neurons. Brain Res 1395:94–107. https://doi.org/10.1016/j.brainres.2011.04.036
Kim HJ, Jeon BS, Yoon MY, Park SS, Lee KW (2012) Increased expression of alpha-synuclein by SNCA duplication is associated with resistance to toxic stimuli. J Mol Neurosci 47:249–255. https://doi.org/10.1007/s12031-012-9732-6
Kitada T et al (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605–608. https://doi.org/10.1038/33416
Knott GJ, Doudna JA (2018) CRISPR-Cas guides the future of genetic engineering. Science 361(6405):866–869. https://doi.org/10.1126/science.aat5011
Lazarou M et al (2015) The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature 524(7565):309–314. https://doi.org/10.1038/nature14893
Lesage S et al (2015) Loss-of-function mutations in RAB39B are associated with typical early-onset Parkinson disease. Neurol Genet 1(1):e9. https://doi.org/10.1212/nxg.0000000000000009
Li JY et al (2008) Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 14:501–503. https://doi.org/10.1038/nm1746
Li W et al (2016) Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci USA 113(23):6544–6549. https://doi.org/10.1073/pnas.1605245113
Liao HK et al (2017) In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation. Cell 171(7):1495–1507. https://doi.org/10.1016/j.cell.2017.10.025
Liddelow SA et al (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481–487. https://doi.org/10.1038/nature21029
Lincoln SJ et al (2003) Parkin variants in North American Parkinson’s disease: cases and controls. Mov Disord 18:1306–1311. https://doi.org/10.1002/mds.10601
Lindvall O et al (1990) Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Science 247(4942):574–577
Liu XS et al (2018) Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell 172(5):979–992. https://doi.org/10.1016/j.cell.2018.01.012
Lohmann E et al (2003) How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 54:176–185. https://doi.org/10.1002/ana.10613
Lubbe S, Morris HR (2014) Recent advances in Parkinson’s disease genetics. J Neurol 261:259–266. https://doi.org/10.1007/s00415-013-7003-2
Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, Lee VM (2012) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338(6109):949–953. https://doi.org/10.1126/science.1227157
Luo J et al (2019) Utilization of the CRISPR-Cas9 gene editing system to dissect neuroinflammatory and neuropharmacological mechanisms in parkinson’s disease. J Neuroimmune Pharmacol. https://doi.org/10.1007/s11481-019-09844-3
Marin I (2008) Ancient origin of the Parkinson disease gene LRRK2. J Mol Evol 67(1):41–50. https://doi.org/10.1007/s00239-008-9122-4
Matsumoto L, Takuma H, Tamaoka A, Kurisaki H, Date H, Tsuji S, Iwata A (2010) CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson’s disease. PLoS ONE 5:e15522. https://doi.org/10.1371/journal.pone.0015522
McCormack AL, Mak SK, Henderson JM, Bumcrot D, Farrer MJ, Di Monte DA (2010) Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS ONE 5:e12122. https://doi.org/10.1371/journal.pone.0012122
McCoy MK, Kaganovich A, Rudenko IN, Ding J, Cookson MR (2014) Hexokinase activity is required for recruitment of parkin to depolarized mitochondria. Hum Mol Genet 23:145–156. https://doi.org/10.1093/hmg/ddt407
Meier ID et al (2010) Short DNA sequences inserted for gene targeting can accidentally interfere with off-target gene expression. FASEB J 24:1714–1724. https://doi.org/10.1096/fj.09-140749
Mori H et al (1998) Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 51(3):890–892
Murlidharan G et al (2016) CNS-restricted transduction and CRISPR/Cas9-mediated gene deletion with an engineered AAV vector. Mol Ther 5:e338. https://doi.org/10.1038/mtna.2016.49
Nasrolahi A et al (2019) Immune system and new avenues in Parkinson’s disease research and treatment. Rev Neurosci. https://doi.org/10.1515/revneuro-2018-0105
Neal M et al (2018) Prokineticin-2 promotes chemotaxis and alternative A2 reactivity of astrocytes. Glia 66(10):2137–2157. https://doi.org/10.1002/glia.23467
Neumann J et al (2009) Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 132:1783–1794. https://doi.org/10.1093/brain/awp044
Nguyen HN et al (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell stem cell 8(3):267–280. https://doi.org/10.1016/j.stem.2011.01.013
Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31(7):763–780. https://doi.org/10.1002/humu.21277
Osterstock G et al (2010) Ghrelin stimulation of growth hormone-releasing hormone neurons is direct in the arcuate nucleus. PLoS ONE 5:e9159. https://doi.org/10.1371/journal.pone.0009159
Panicker N, Dawson VL, Dawson TM (2017) Activation mechanisms of the E3 ubiquitin ligase parkin. Biochem J 474(18):3075–3086. https://doi.org/10.1042/bcj20170476
Piccini P et al (2005) Factors affecting the clinical outcome after neural transplantation in Parkinson’s disease. Brain 128:2977–2986. https://doi.org/10.1093/brain/awh649
Piper DA, Sastre D, Schule B (2018) Advancing stem cell models of alpha-synuclein gene regulation in neurodegenerative disease. Front Neurosci 12:199. https://doi.org/10.3389/fnins.2018.00199
Pitteloud N et al (2007) Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 104(44):17447–17452. https://doi.org/10.1073/pnas.0707173104
Politis M et al (2010) Serotonergic neurons mediate dyskinesia side effects in Parkinson’s patients with neural transplants. Sci Transl Med 2(38):38ra46. https://doi.org/10.1126/scitranslmed.3000976
Polymeropoulos MH et al (1996) Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23. Science 274(5290):1197–1199
Potting C et al (2018) Genome-wide CRISPR screen for PARKIN regulators reveals transcriptional repression as a determinant of mitophagy. Proc Natl Acad Sci USA 115:E180–E189. https://doi.org/10.1073/pnas.1711023115
Pramstaller PP et al (2005) Lewy body Parkinson’s disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 58(3):411–422. https://doi.org/10.1002/ana.20587
Qing X, Walter J, Jarazo J, Arias-Fuenzalida J, Hillje AL, Schwamborn JC (2017) CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and alpha-Synuclein modulation in dopaminergic neurons. Stem Cell Res 24:44–50. https://doi.org/10.1016/j.scr.2017.08.013
Ran FA et al (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154(6):1380–1389. https://doi.org/10.1016/j.cell.2013.08.021
Reinhardt P et al (2013) Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling. PLoS ONE 8:e59252. https://doi.org/10.1371/journal.pone.0059252
Rose CM et al (2016) Highly multiplexed quantitative mass spectrometry analysis of ubiquitylomes. Cell Syst 3(395–403):e394. https://doi.org/10.1016/j.cels.2016.08.009
Safari F, Tamaddon AM, Zarghami N, Abolmali S, Akbarzadeh A (2016) Polyelectrolyte complexes of hTERT siRNA and polyethyleneimine: effect of degree of PEG grafting on biological and cellular activity. Artif Cells Nanomed Biotechnol 44(6):1561–1568. https://doi.org/10.3109/21691401.2015.1064936
Safari F, Rahmani Barouji S, Tamaddon AM (2017) Strategies for improving siRNA-induced gene silencing efficiency. Adv Pharm Bull 7:603–609. https://doi.org/10.15171/apb.2017.072
Safari F, Zare K, Negahdaripour M, Barekati-Mowahed M, Ghasemi Y (2019) CRISPR Cpf1 proteins: structure, function and implications for genome editing. Cell Biosci 9:36. https://doi.org/10.1186/s13578-019-0298-7
Samaranch L et al (2010) PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 133(4):1128–1142. https://doi.org/10.1093/brain/awq051
Sanchez-Danes A et al (2012) Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson’s disease. EMBO Mol Med 4:380–395. https://doi.org/10.1002/emmm.201200215
Sanders LH et al (2014) LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson’s disease patients: reversal by gene correction. Neurobiol Dis 62:381–386. https://doi.org/10.1016/j.nbd.2013.10.013
Sarkar S et al (2017) Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson’s disease. NPJ 3(1):30. https://doi.org/10.1038/s41531-017-0032-2
Schrag A (2018) Testing the MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 33:1518–1520. https://doi.org/10.1002/mds.27543
Scott L, Dawson VL, Dawson TM (2017) Trumping neurodegeneration: targeting common pathways regulated by autosomal recessive Parkinson’s disease genes. Exp Neurol 298:191–201. https://doi.org/10.1016/j.expneurol.2017.04.008
Shi L et al (2013) Peptide hormone ghrelin enhances neuronal excitability by inhibition of Kv7/KCNQ channels. Nat Commun 4:1435. https://doi.org/10.1038/ncomms2439
Solberg N, Krauss S (2013) Luciferase assay to study the activity of a cloned promoter DNA fragment. Methods Mol Biol 977:65–78. https://doi.org/10.1007/978-1-62703-284-1_6
Soldner F et al (2016) Parkinson-associated risk variant in distal enhancer of alpha-synuclein modulates target gene expression. Nature 533:95–99. https://doi.org/10.1038/nature17939
Song C et al (2019) Mechanistic interplay between autophagy and apoptotic signaling in endosulfan-induced dopaminergic neurotoxicity: relevance to the adverse outcome pathway in pesticide neurotoxicity. Toxicol Sci. https://doi.org/10.1093/toxsci/kfz049
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840. https://doi.org/10.1038/42166
Suda Y et al (2018) Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson’s disease-like motor dysfunction. Mol Brain 11:6. https://doi.org/10.1186/s13041-018-0349-8
Taghavi S et al (2018) A clinical and molecular genetic study of 50 families with autosomal recessive parkinsonism revealed known and novel gene mutations. Mol Neurobiol 55(4):3477–3489. https://doi.org/10.1007/s12035-017-0535-1
Tagliafierro L, Chiba-Falek O (2016) Up-regulation of SNCA gene expression: implications to synucleinopathies. Neurogenetics 17:145–157. https://doi.org/10.1007/s10048-016-0478-0
Taipa R, Pereira C, Reis I, Alonso I, Bastos-Lima A, Melo-Pires M, Magalhaes M (2016) DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology. Brain 139(6):1680–1687. https://doi.org/10.1093/brain/aww080
Takahashi M et al (2015) Normalization of overexpressed alpha-synuclein causing parkinson’s disease by a moderate gene silencing with rna interference. Mol Ther 4:e241. https://doi.org/10.1038/mtna.2015.14
Valente EM et al (2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304(5674):1158–1160. https://doi.org/10.1126/science.1096284
Vasil’eva EA, Melino D, Barlev NA (2015) CRISPR/Cas system for genome editing in pluripotent stem cells. Tsitologiia 57(1):19–30
Vetchinova AS et al (2018) Cytogenetic analysis of the results of genome editing on the cell model of parkinson’s disease. Bull Exp Biol Med. https://doi.org/10.1007/s10517-018-4174-y
Volpicelli-Daley LA et al (2011) Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72:57–71. https://doi.org/10.1016/j.neuron.2011.08.033
Wang Y, Wang X, Li R, Yang ZF, Wang YZ, Gong XL, Wang XM (2013) A DNA methyltransferase inhibitor, 5-aza-2′-deoxycytidine, exacerbates neurotoxicity and upregulates Parkinson’s disease-related genes in dopaminergic neurons. CNS Neurosci Ther 19(3):183–190. https://doi.org/10.1111/cns.12059
Wang X et al (2016) One-step generation of triple gene-targeted pigs using CRISPR/Cas9 system. Sci Rep 6:20620. https://doi.org/10.1038/srep20620
Wilson GR et al (2014) Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with alpha-synuclein pathology. Am J Hum Genet 95(6):729–735. https://doi.org/10.1016/j.ajhg.2014.10.015
Yao J, Huang J, Zhao J (2016) Genome editing revolutionize the creation of genetically modified pigs for modeling human diseases. Hum Genet 135:1093–1105. https://doi.org/10.1007/s00439-016-1710-6
Ye L et al (2014) Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA 111(26):9591–9596. https://doi.org/10.1073/pnas.1407473111
Zhang D, Kanthasamy A, Yang Y, Anantharam V, Kanthasamy A (2007) Protein kinase C delta negatively regulates tyrosine hydroxylase activity and dopamine synthesis by enhancing protein phosphatase-2A activity in dopaminergic neurons. J Neurosci 27(20):5349–5362. https://doi.org/10.1523/jneurosci.4107-06.2007
Zhu M (1861) S HP, Han S (2017) DJ-1, a Parkinson’s disease related protein, aggregates under denaturing conditions and co-aggregates with alpha-synuclein through hydrophobic interaction. Biochim et Biophys Acta 7:1759–1769. https://doi.org/10.1016/j.bbagen.2017.03.013
Zhu XX, Zhong YZ, Ge YW, Lu KH, Lu SS (2018) CRISPR/Cas9-mediated generation of guangxi bama minipigs harboring three mutations in alpha-synuclein causing parkinson’s disease. Sci Rep 8(1):12420. https://doi.org/10.1038/s41598-018-30436-3
Zimprich A et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44(4):601–607. https://doi.org/10.1016/j.neuron.2004.11.005
Zou J, Mali P, Huang X, Dowey SN, Cheng L (2011) Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 118:4599–4608. https://doi.org/10.1182/blood-2011-02-335554
Funding
It is certified that no funding has been received for the preparation of this manuscript
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed Consent
As no human participants are involved in this study no informed consent had been obtained.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Safari, F., Hatam, G., Behbahani, A.B. et al. CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson’s Disease. Cell Mol Neurobiol 40, 477–493 (2020). https://doi.org/10.1007/s10571-019-00761-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-019-00761-w